Hartford Investment Management Co. lessened its stake in Hologic, Inc. (NASDAQ:HOLX) by 4.4% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 63,845 shares of the medical equipment provider’s stock after selling 2,938 shares during the period. Hartford Investment Management Co.’s holdings in Hologic were worth $2,342,000 at the end of the most recent quarter.
A number of other institutional investors also recently bought and sold shares of HOLX. Koch Industries Inc. grew its stake in shares of Hologic by 15,554.1% in the second quarter. Koch Industries Inc. now owns 1,149,481 shares of the medical equipment provider’s stock worth $1,125,000 after acquiring an additional 1,142,138 shares in the last quarter. Picton Mahoney Asset Management grew its stake in shares of Hologic by 8.1% in the second quarter. Picton Mahoney Asset Management now owns 57,150 shares of the medical equipment provider’s stock worth $2,593,000 after acquiring an additional 4,300 shares in the last quarter. Swiss National Bank grew its stake in shares of Hologic by 12.8% in the second quarter. Swiss National Bank now owns 1,159,424 shares of the medical equipment provider’s stock worth $52,615,000 after acquiring an additional 131,300 shares in the last quarter. Rhumbline Advisers grew its stake in shares of Hologic by 1.4% in the second quarter. Rhumbline Advisers now owns 548,465 shares of the medical equipment provider’s stock worth $24,889,000 after acquiring an additional 7,727 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. grew its stake in shares of Hologic by 68.5% in the second quarter. Robeco Institutional Asset Management B.V. now owns 42,267 shares of the medical equipment provider’s stock worth $1,919,000 after acquiring an additional 17,180 shares in the last quarter. Hedge funds and other institutional investors own 98.09% of the company’s stock.
Several equities analysts have commented on the stock. Zacks Investment Research upgraded shares of Hologic from a “sell” rating to a “hold” rating in a research note on Tuesday, October 31st. Needham & Company LLC restated a “buy” rating and issued a $50.00 price target on shares of Hologic in a research note on Friday, November 3rd. Stifel Nicolaus restated a “buy” rating and issued a $45.00 price target (down previously from $48.00) on shares of Hologic in a research note on Monday, October 9th. BidaskClub downgraded shares of Hologic from a “hold” rating to a “sell” rating in a research note on Wednesday, August 9th. Finally, Jefferies Group restated a “buy” rating and issued a $44.00 price target (down previously from $49.00) on shares of Hologic in a research note on Tuesday, October 10th. One analyst has rated the stock with a sell rating, five have given a hold rating and nine have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $47.54.
In other news, Director Elaine Ullian sold 9,282 shares of Hologic stock in a transaction on Monday, November 13th. The shares were sold at an average price of $40.50, for a total transaction of $375,921.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Lawrence M. Levy sold 9,596 shares of Hologic stock in a transaction on Tuesday, October 10th. The stock was sold at an average price of $36.81, for a total transaction of $353,228.76. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 35,972 shares of company stock valued at $1,385,977. Corporate insiders own 0.79% of the company’s stock.
Shares of Hologic, Inc. (NASDAQ:HOLX) opened at $41.85 on Tuesday. The stock has a market cap of $11,261.67, a price-to-earnings ratio of 20.22, a PEG ratio of 1.97 and a beta of 0.95. Hologic, Inc. has a 1 year low of $35.76 and a 1 year high of $46.80. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.61 and a current ratio of 0.79.
Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.49 by $0.01. The business had revenue of $802.90 million during the quarter, compared to analysts’ expectations of $792.54 million. Hologic had a net margin of 24.70% and a return on equity of 21.69%. The company’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.52 EPS. research analysts anticipate that Hologic, Inc. will post 2.12 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Hartford Investment Management Co. Reduces Position in Hologic, Inc. (HOLX)” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://www.dispatchtribunal.com/2017/12/05/hartford-investment-management-co-reduces-position-in-hologic-inc-holx.html.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.